Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

被引：24

作者：

Yasuda, Yuichiro ^{[1
]}

Urata, Yoshiko ^{[1
]}

Tohnai, Rie ^{[1
]}

Ito, Shoichi ^{[1
]}

Kawa, Yoshitaka ^{[1
]}

Kono, Yuko ^{[1
]}

Hattori, Yoshihiro ^{[1
]}

Tsuda, Masahiro ^{[2
]}

Sakuma, Toshiko ^{[3
]}

Negoro, Shunichi ^{[1
]}

Satouchi, Miyako ^{[1
]}

机构：

[1] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan

[2] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan

[3] Hyogo Canc Ctr, Dept Diagnost Pathol, Akashi, Hyogo, Japan

来源：

INTERNAL MEDICINE | 2018年 / 57卷 / 09期

关键词：

nivolumab; immune-related adverse event; colitis; non-small cell lung cancer; immune-checkpoint-inhibitor; MANAGEMENT; DOCETAXEL; BLOCKADE;

D O I：

10.2169/internalmedicine.9230-17

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg every 2 weeks for advanced lung adenocarcinoma. The patient was admitted to our hospital due to non-bloody watery diarrhea after the 70th dose of nivolumab. A biopsy specimen of the colon mucosa revealed evidence of colitis with cryptitis and crypt microabscesses. He was diagnosed with immune-related colitis and started on predonisolone 60 mg/day. Subsequently, his symptoms remarkably resolved. Consideration of immune-related adverse events up to several years after the initiation of nivolumab is important.

引用

页码：1269 / 1272

页数：4

共 10 条

[1] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Beck, Kimberly E.
Blansfield, Joseph A.
Tran, Khoi Q.
Feldman, Andrew L.
Hughes, Marybeth S.
Royal, Richard E.
Kammula, Udai S.
Topalian, Suzanne L.
Sherry, Richard M.
Kleiner, David
Quezado, Martha
Lowy, Israel
Yellin, Michael
Rosenberg, Steven A.
Yang, James C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2283 - 2289
[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Borghaei, H.
Paz-Ares, L.
Horn, L.
Spigel, D. R.
Steins, M.
Ready, N. E.
Chow, L. Q.
Vokes, E. E.
Felip, E.
Holgado, E.
Barlesi, F.
Kohlhaeufl, M.
Arrieta, O.
Burgio, M. A.
Fayette, J.
Lena, H.
Poddubskaya, E.
Gerber, D. E.
Gettinger, S. N.
Rudin, C. M.
Rizvi, N.
Crino, L.
Blumenschein, G. R.
Antonia, S. J.
Dorange, C.
Harbison, C. T.
Finckenstein, F. Graf
Brahmer, J. R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
[3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Brahmer, Julie
Reckamp, Karen L.
Baas, Paul
Crino, Lucio
Eberhardt, Wilfried E. E.
Poddubskaya, Elena
Antonia, Scott
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David
Ready, Neal
Gainor, Justin
Aren Frontera, Osvaldo
Havel, Libor
Steins, Martin
Garassino, Marina C.
Aerts, Joachim G.
Domine, Manuel
Paz-Ares, Luis
Reck, Martin
Baudelet, Christine
Harbison, Christopher T.
Lestini, Brian
Spigel, David R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
[4] Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Eigentler, Thomas K.
Hassel, Jessica C.
Berking, Carola
Aberle, Jens
Bachmann, Oliver
Gruenwald, Viktor
Kaehler, Katharina C.
Loquai, Carmen
Reinmuth, Niels
Steins, Martin
Zimmer, Lisa
Sendl, Anna
Gutzmer, Ralf
[J]. CANCER TREATMENT REVIEWS, 2016, 45 : 7 - 18
[5] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M.
Bigenwald, C.
Champiat, S.
Collins, M.
Carbonnel, F.
Postel-Vinay, S.
Berdelou, A.
Varga, A.
Bahleda, R.
Hollebecque, A.
Massard, C.
Fuerea, A.
Ribrag, V.
Gazzah, A.
Armand, J. P.
Amellal, N.
Angevin, E.
Noel, N.
Boutros, C.
Mateus, C.
Robert, C.
Soria, J. C.
Marabelle, A.
Lambotte, O.
[J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : 139 - 148
[6] Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy
Nishino, Mizuki
Sholl, Lynette M.
Hodi, F. Stephen
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) : 288 - 290
[7] Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Rizvi, Naiyer A.
Mazieres, Julien
Planchard, David
Stinchcombe, Thomas E.
Dy, Grace K.
Antonia, Scott J.
Horn, Leora
Lena, Herve
Minenza, Elisa
Mennecier, Bertrand
Otterson, Gregory A.
Campos, Luis T.
Gandara, David R.
Levy, Benjamin P.
Nair, Suresh G.
Zalcman, Gerard
Wolf, Juergen
Souquet, Pierre-Jean
Baldini, Editta
Cappuzzo, Federico
Chouaid, Christos
Dowlati, Afshin
Sanborn, Rachel
Lopez-Chavez, Ariel
Grohe, Christian
Huber, Rudolf M.
Harbison, Christopher T.
Baudelet, Christine
Lestini, Brian J.
Ramalingam, Suresh S.
[J]. LANCET ONCOLOGY, 2015, 16 (03) : 257 - 265
[8] Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, Caroline
Schachter, Jacob
Long, Georgina V.
Arance, Ana
Grob, Jean Jacques
Mortier, Laurent
Daud, Adil
Carlino, Matteo S.
McNeil, Catriona
Lotem, Michal
Larkin, James
Lorigan, Paul
Neyns, Bart
Blank, Christian U.
Hamid, Omid
Mateus, Christine
Shapira-Frommer, Ronnie
Kosh, Michele
Zhou, Honghong
Ibrahim, Nageatte
Ebbinghaus, Scot
Ribas, Antoni
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2521 - 2532
[9] Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, Suzanne L.
Drake, Charles G.
Pardoll, Drew M.
[J]. CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) : 207 - 212
[10] Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Villadolid, Jeryl
Amin, Asim
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 560 - 575

← 1 →